Sanofi : FDA accepts for priority review Dupixent® (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Sanofi : Sanofi Completes Acquisition of Synthorx, Inc.

Sanofi : Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Synthorx

Sanofi : Availability of the Pre-quarterly Results Communication

Sanofi commences tender offer for acquisition of Synthorx, Inc.

Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)

Sanofi : Positive results presented from pivotal Phase 3 trial of sutimlimab in people with cold agglutinin disease

Sanofi CEO unveils new strategy to drive innovation and growth

Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion

Sanofi : FDA approves Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for adults 65 years of age and older